Diabetes
Glooko Secures $100 Million Funding to Enhance Diabetes Management Platform Under New Leadership
Glooko, diabetes management, healthcare technology, funding, new leadership
Kailera Secures $400M Funding to Advance China-Developed Obesity and Diabetes Therapies
Kailera, obesity, diabetes, China-developed drugs, $400M funding, pharmaceuticals, biotech
Novo Nordisk’s Ozempic Expected to Face Medicare Price Negotiations in 2025
Ozempic, Medicare, price negotiations, Novo Nordisk, diabetes medication, Inflation Reduction Act
Lilly’s Weekly Insulin Candidate Efsitora Alfa Shows Promising Results in Phase III Trials
Eli Lilly, Efsitora Alfa, Weekly Insulin, Type 1 Diabetes, Type 2 Diabetes, Phase III Trials, QWINT Studies, Diabetes Treatment
EASD24: Lilly’s Weekly Insulin Efsitora Demonstrates Efficacy but Raises Hypoglycemia Concerns
Eli Lilly, EASD24, Weekly Insulin, Efsitora, Type 1 Diabetes, Type 2 Diabetes, Hypoglycemia, Insulin Therapy
Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials
Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.
Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials
Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management
Novo Nordisk Unveils Enhanced Cardiovascular Benefits of Semaglutide in Post-Hoc Analysis
Semaglutide, Cardiovascular Outcomes, Obesity, Type 2 Diabetes, Novo Nordisk, Post-Hoc Analysis
Semaglutide and Mental Health: A Complex Relationship
semaglutide, mental health, suicidal ideation, GLP-1 drugs, weight loss, diabetes
Alaskans Can Virtually Manage Diabetes Risk for Free with Omada Health
Omada Health, Diabetes Management, Virtual Chronic Care, Alaska, Free Program